TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04991259

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Renal Replacement Therapy (CRRT)
Description: Continuous renal replacement therapy will be administered as continuous venovenous hemodiafiltration (CVVHDF) using Prisma and Prismaflex (Gambro) devices, with blood flows ranging from 150-180 mL/hr and target effluent rates of 20 - 25 mL/kg/hr. Anticoagulation was not used during dialysis. CRRT would be continued until resolution of cerebral edema and in decrease in ammonia levels below 150 ug/dl or in those who develop adverse effects of therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Renal Replacement Therapy (CRRT)
Description: Continuous renal replacement therapy will be administered as continuous venovenous hemodiafiltration (CVVHDF) using Prisma and Prismaflex (Gambro) devices, with blood flows ranging from 150-180 mL/hr and target effluent rates of 20 - 25 mL/kg/hr. Anticoagulation was not used during dialysis. CRRT would be continued until resolution of cerebral edema and in decrease in ammonia levels below 150 ug/dl or in those who develop adverse effects of therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: In the L- ICU, patients will be managed by a multidisciplinary team. Intubation and ventilation will be undertaken for standard indications in addition to the development of grade 3 encephalopathy or evidence of cerebral edema on CT-scan. Fluid management will be done with crystalloids, with the use of colloids (5% albumin) in patients with severe hypoalbuminemia (serum albumin less than 2.5gm/dl). Norepinephrine will be the primary vasopressor used to target a mean arterial pressure of 65-70 mm of Hg. with adjunctive use of intravenous low dose hydrocortisone and vasopressin in patients not responsive to initial therapy.
Study: NCT04251351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Paracetamol 15 mg/kg/dose IV 6 hourly for 72 hours

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Mechanical antipyresis
Description: Mechanical antipyresis (i.e. loose clothing, tepid sponging, fanning and cooling blanket) if fever in the first 72 hours.~If a temperature \>38.5°C persists despite mechanical antipyresis, or if deemed necessary by the treating clinician, then paracetamol can be administered according to local practice (paracetamol IV 15 mg/kg as needed).
Study: NCT05811728

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low level laser therapy
Description: The low-level laser applied will be a Diode laser\* emitting infrared radiation at a wavelength of 980 nm, in a continuous mode. On the experimental side, subjects will receive LLLT on days 0, 3, 7, 14, and every 2 weeks thereafter, till the termination of the study period (3 months).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: without beam emission
Description: The laser tip will be held passively on the control side without beam emission, providing a placebo effect.
Study: NCT05769842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Propofol was mainly used in the intervention group during anesthesia extubation. Propofol was given a small amount of times about 1\~2mg/kg before extubation when the patient recovered spontaneously.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: normal saline
Description: Same dose as propofol.
Study: NCT05549141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treadmill gait training with gait facilitators
Description: 6 sessions of 30 minutes each of treadmill gait training with functional electrical stimulation as a gait facilitator
Study: NCT06614309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Progressive Carbon Dioxide
Description: The progressive carbon dioxide visit will include a 60-minute progressive ramp which includes 6 cycles of progressive CO2 ramping starting at 0% and progressing up to 10% within 5 minutes immediately followed with 5 minutes of room air breathing in between cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Progressive Carbon Dioxide
Description: The progressive carbon dioxide visit will include a 60-minute progressive ramp which includes 6 cycles of progressive CO2 ramping starting at 0% and progressing up to 10% within 5 minutes immediately followed with 5 minutes of room air breathing in between cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Progressive Carbon Dioxide
Description: The progressive carbon dioxide visit will include a 60-minute progressive ramp which includes 6 cycles of progressive CO2 ramping starting at 0% and progressing up to 10% within 5 minutes immediately followed with 5 minutes of room air breathing in between cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: The intermittent hypoxia exposure visit will include 6 cycles breathing 8-12% oxygen (O2) for 5 minutes with a target pulse oximeter saturation of 86-90%, followed by 5 minutes of breathing room air.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: The intermittent hypoxia exposure visit will include 6 cycles breathing 8-12% oxygen (O2) for 5 minutes with a target pulse oximeter saturation of 86-90%, followed by 5 minutes of breathing room air.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: The intermittent hypoxia exposure visit will include 6 cycles breathing 8-12% oxygen (O2) for 5 minutes with a target pulse oximeter saturation of 86-90%, followed by 5 minutes of breathing room air.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: The intermittent hypoxia exposure visit will include 6 cycles breathing 8-12% oxygen (O2) for 5 minutes with a target pulse oximeter saturation of 86-90%, followed by 5 minutes of breathing room air.
Study: NCT04990791

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin 75mg
Description: Aspirin 75mg OD for 14 days

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin 75mg
Description: Aspirin 75mg OD for 14 days
Study: NCT06614309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: The intermittent hypoxia exposure visit will include 6 cycles breathing 8-12% oxygen (O2) for 5 minutes with a target pulse oximeter saturation of 86-90%, followed by 5 minutes of breathing room air.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: The intermittent hypoxia exposure visit will include 6 cycles breathing 8-12% oxygen (O2) for 5 minutes with a target pulse oximeter saturation of 86-90%, followed by 5 minutes of breathing room air.
Study: NCT04990791

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin 20mg
Description: Aspirin 20mg BD for 14 days

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin 20mg
Description: Aspirin 20mg BD for 14 days

Intervention type: DRUG
Group type: OTHER
Intervention: Rivaroxaban 2.5 mg
Description: Rivaroxaban 2.5mg BD

Intervention type: DRUG
Group type: OTHER
Intervention: Rivaroxaban 2.5 mg
Description: Rivaroxaban 2.5mg BD
Study: NCT05549141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treadmill gait training with gait facilitators
Description: 6 sessions of 30 minutes each of treadmill gait training with functional electrical stimulation as a gait facilitator

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treadmill gait training not-associated with gait facilitators
Description: 6 sessions of 30 minutes each of treadmill gait training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treadmill gait training not-associated with gait facilitators
Description: 6 sessions of 30 minutes each of treadmill gait training
Study: NCT04655105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: root canal rotary files
Description: post operative pain evaluation using different rotary file system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: root canal rotary files
Description: post operative pain evaluation using different rotary file system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: root canal rotary files
Description: post operative pain evaluation using different rotary file system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: root canal rotary files
Description: post operative pain evaluation using different rotary file system
Study: NCT06342726

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PAX Warming Blanket
Description: Electric resistive active external warming blanket

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Passive insulation
Description: 3-layered wrapping model

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Passive insulation
Description: 3-layered wrapping model
Study: NCT05996731

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: A punch biopsy is a 15-minute low-risk procedure performed through a sterile circular blade (usually 3-4 mm) under local anesthesia. Briefly, the instrument is rotated down through the forearm epidermis and dermis perpendicular to its physiological lines of relaxation and into the subcutaneous fat, by producing a cylindrical core. Punch biopsy site can be closed with a single suture and generally produce only a minimal scar.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin biopsy
Description: A punch biopsy is a 15-minute low-risk procedure performed through a sterile circular blade (usually 3-4 mm) under local anesthesia. Briefly, the instrument is rotated down through the forearm epidermis and dermis perpendicular to its physiological lines of relaxation and into the subcutaneous fat, by producing a cylindrical core. Punch biopsy site can be closed with a single suture and generally produce only a minimal scar.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: A punch biopsy is a 15-minute low-risk procedure performed through a sterile circular blade (usually 3-4 mm) under local anesthesia. Briefly, the instrument is rotated down through the forearm epidermis and dermis perpendicular to its physiological lines of relaxation and into the subcutaneous fat, by producing a cylindrical core. Punch biopsy site can be closed with a single suture and generally produce only a minimal scar.
Study: NCT06614309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training: Progressive Carbon Dioxide Ramping
Description: Intervention will consist of 6 to 10 study visits (3-5 sessions/week) to be completed within 14 days. Subjects will will be given the progressive CO2 ramp protocol of 60-minute sessions, which will include 6 cycles of progressive CO2 ramping starting at 0% and progressing up to 10% within 5 minutes immediately followed with 5 minutes of room air breathing in between cycles, for every visit during the 14 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training: Intermittent Hypoxic Exposure
Description: Intervention will consist of 6 to 10 study visits (3-5 sessions/week) to be completed within 14 days. Subjects will will be given the intermittent hypoxia exposure protocol of 60-minute sessions, which will include 6 cycles breathing 8-12% oxygen (O2) for 5 minutes with a target pulse oximeter saturation of 86-90%, followed by 5 minutes of breathing room air for every visit during the 14 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Training: Placebo Control
Description: Intervention will consist of 6 to 10 study visits (3-5 sessions/week) to be completed within 14 days. Subjects will complete 6 simulated cycles of 5 minutes breathing 21% oxygen from a douglas bag and 5 minutes breathing room air (60 minutes) for every visit during the 14 days.
Study: NCT06616558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen SPF 70
Description: Participants will topically apply sunscreen SPF 70

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen SPF 70
Description: On the randomized side of the half-face, the product will be applied by a qualified technician
Study: NCT06616792

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dexamethasone phonophoresis
Description: Ultrasound therapeutic device with the use of 0.4% Dexamethasone sodium phosphate gel for phonophoresis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Acupuncture
Description: low level laser therapy placed in contact with the skin perpendicular over the body acupoints (LI 4) - (LI 20) - (EX- HN5) - (GV 20) - (GV 24) - (ST3) - (ST 7) in both sides and on (EX-HN3) acupoint,

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional medication
Description: Each participant in this group receive the traditional medication.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional medication
Description: Each participant in this group receive the traditional medication.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional medication
Description: Each participant in this group receive the traditional medication.
Study: NCT06677827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: External Oblique Intercostal plane block technique with 20 ml bupivacaine 0.25% only bilateral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate and Bupivacaine 0.125%
Description: External Oblique Intercostal plane block technique with 20 ml bupivacaine 0.25%+200 mg magnesium sulphate bilateral
Study: NCT06677658

Intervention type: DIETARY_SUPPLEMENT
Intervention: Olive Oil
Description: Group 1 included patients who consumed at least 20 ml of oral olive oil daily. Group 2 included patients who did not consume olive oil.

Intervention type: DRUG
Intervention: Methylprednisolone
Description: Both groups were diagnosed with Covid-19 pneumonia and were given pulse steroid ( methylprednisolone ) treatment at 250 mg/day for 3 days.

Intervention type: DRUG
Intervention: Methylprednisolone
Description: Both groups were diagnosed with Covid-19 pneumonia and were given pulse steroid ( methylprednisolone ) treatment at 250 mg/day for 3 days.
Study: NCT06679374

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take one pill (.5 milligrams) a day for days 1-3 and then one pill (.5 milligrams) in the morning and one pill in the evening days 4-30 and months 2-12. In month 13 participants will take one pill in the morning days 1-3. Participants will be off study drug month 13 days 4-30.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Participants will take one pill (.5 milligrams) a day for days 1-3 and then one pill (.5 milligrams) in the morning and one pill in the evening days 4-30 and months 2-12. In month 13 participants will take one pill in the morning days 1-3. Participants will be off study drug month 13 days 4-30.
Study: NCT06679010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online group counseling
Description: The program progresses as one weekly group session over 10 weeks, each with its own topic. The core components of the program include psychoeducation, training self-compassion and acceptance, cognitive restructuring, interpersonal skills training, systems and management of daily life activities, prevention of conflicts, and the mother-baby relation. Participants will meet online as a group together with the instructor, a consultant from the ADHD Association, who will lead and facilitate the sessions. Before each session, there is a podcast episode that covers the topic of each session. The 10 podcasts feature interviews with clinicians, researchers, and women with ADHD, focusing on the themes from the program's sessions.
Study: NCT04522804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin is a classic psychedelic of medium duration that is well-tolerated and has a documented safety and efficacy record that makes it uniquely well-suited to the existential issues that arise in this patient population. Psilocybin has been described as an 'existential medicine' given patient testimonials as to its acute and lasting effects on interpersonal connection, ability to more deeply engage with meaningful activities and relationships, dramatic reductions in fear of death, and a renewed sense of well-being.
Study: NCT06237101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of remifentanil
Description: The dose of remifentanil will be changed to determine the concentration of propofol at which burst suppressions are generated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medium dose of remifentanil
Description: The dose of remifentanil will be changed to determine the concentration of propofol at which burst suppressions are generated
Study: NCT05796596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Virtual Reality (VR) distraction
Description: Children in the VR distraction group will begin interacting with the virtual environment (VE) 2 minutes prior to the skin prick test and will continue playing throughout. The VR environment is a game in which the child draw a 360 degree image.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Distraction by the book
Description: In the book distraction group, the child will be invited to find and count animals in various landscapes. The book will be given 2 minutes prior to the skin prick test and continued reading throughout.
Study: NCT05373641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeated feedback
Description: Repeated feedback monthly based on previous month pain documentation audit results.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain documentation audit
Description: Monthly pain documentation audit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain documentation audit
Description: Monthly pain documentation audit
Study: NCT06044389

Intervention type: DEVICE
Intervention: Fructosin
Description: Fructosin® is a CE marked medical device. The capsules with 30.23 mg xylose isomerase are taken as recommended. This means that, depending on the total intake, 1-2 capsules are to be taken with water 15 minutes before meals containing fructose, a maximum of 3 times a day.~Use as needed during the 4-week intake phase.
Study: NCT05744011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tango intervention
Description: The interventions will be implemented by ABB Reportages and will be carried out by nursing staff who had previously received training in therapeutic tango at the University of Burgundy.~A dance movement therapist and a musician will accompany the interventions twice a month.~Participants will attend a 1-hour tango session, twice a week for twelve weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adapted Physical Activity
Description: The intervention will be carried out by an Adapted Physical Activity professor and by nursing staff.~Music is prohibited during the sessions. Participants will attend a 1-hour APA, twice a week for twelve weeks.
Study: NCT05594056

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transorbital ultrasound of the optic nerve sheet
Description: Measurement of the optic nerve sheet with a linear transducer (7,5 MHz).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transorbital ultrasound of the optic nerve sheet
Description: Measurement of the optic nerve sheet with a linear transducer (7,5 MHz).
Study: NCT05263375

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innovalve TMVR system
Description: Innovalve TMVR system
Study: NCT05651139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Vibration Device
Description: An electrical Vibration Massage device will be used to induce deep tissue vibration stimulation
Study: NCT05263167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Aescinate
Description: sodium Aescinate 10mg in 250ml sodium chloride 0.9% infusion bag intravenously once daily for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250ml sodium chloride 0.9% infusion bag intravenously once daily for 10 days.
Study: NCT05545059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Description: In sacubitril/valsartan group, patients will receive amlodipine 10mg, hydrochlorothiazide 25 mg, spironolactone 20 mg, sacubitril/valsartan 200mg to treat. The initial dose of sacubitril/valsartan will be 100mg per day and will be doubled to 200mg per day after 2 weeks then maintain until the end of the 8-week treatment period.
Study: NCT04741711

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: An ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava.
Description: An ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava. The choice of congestion treatment modalities to be implemented is left to the investigators' discretion, in accordance with European practice guidelines.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Usual care without ultrasound guidance
Description: Usual care (i.e. without ultrasound guidance)
Study: NCT05868876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion
Description: AK127 is administered intravenously according to the frequency Q3W and different dosage of administration at different stages.AK104 is administered intravenously according to the frequency and dosage 10mg/kg Q3W.
Study: NCT05808348

Intervention type: OTHER
Intervention: Scales and questionnaires
Description: We will ask participants about their age, gender, height, weight, education level, medical history, number of falls in the last 1 year, status and length of COVID-19-related hospitalizations, and whether they have gotten the COVID-19 vaccine. The participants will be interviewed in person as part of the evaluation process.~The Modified Baecke Physical Activity Questionnaire, the Fall Efficacy Scale-International, and the Numerical Pain Rating Scale will be used to assess the participants' levels of pain, fear of falling, and physical activity, respectively.

Intervention type: OTHER
Intervention: Scales and questionnaires
Description: We will ask participants about their age, gender, height, weight, education level, medical history, number of falls in the last 1 year, status and length of COVID-19-related hospitalizations, and whether they have gotten the COVID-19 vaccine. The participants will be interviewed in person as part of the evaluation process.~The Modified Baecke Physical Activity Questionnaire, the Fall Efficacy Scale-International, and the Numerical Pain Rating Scale will be used to assess the participants' levels of pain, fear of falling, and physical activity, respectively.